Ticagrelor Pharmacology and Clinical Use

Pharmacological Basis

• The American College of Cardiology notes that ticagrelor is an active compound that does not depend on CYP2C19 metabolism for its antiplatelet effect, unlike clopidogrel, and provides reversible P2Y12 receptor inhibition without requiring metabolic activation 1

Contrast with Clopidogrel

• Clopidogrel is a prodrug requiring CYP2C19 conversion to its active metabolite, and CYP2C19 loss-of-function alleles result in reduced active metabolite levels and increased cardiovascular events in clopidogrel-treated patients 2, 3, 4

Guideline Recommendations

• The American College of Cardiology/American Heart Association guidelines state that ticagrelor requires no biotransformation for reversible P2Y12 receptor inhibition, and the clinical utility of genotyping is not rigorously established and is less likely to be necessary for ticagrelor given the lesser degree of variation in response 1

Clinical Implications

• The American College of Cardiology notes that ticagrelor provides consistent antiplatelet effects across all genetic backgrounds, making it particularly valuable in acute settings where rapid treatment decisions are needed, and the standard dosing applies to all patients regardless of genetic background 1

Ticagrelor Mechanism and Clinical Use

Introduction to Ticagrelor

• The American Heart Association acknowledges ticagrelor as a cyclopentyl-triazolopyrimidine, representing a distinct chemical class from thienopyridines, with a mechanism of action that provides reversible P2Y12 receptor inhibition 5, 6, 7

Drug Classification and Pharmacokinetics

• Ticagrelor is not a prodrug and does not require bioactivation through the cytochrome P450 system, unlike clopidogrel and prasugrel, with a rapid onset of action and offset 7, 8, 9, 10, 6
• The European Society of Cardiology recommends ticagrelor as a standard P2Y12 inhibitor for acute coronary syndrome management, with a loading dose of 180 mg and a maintenance dose of 90 mg twice daily 5, 6

Clinical Approval and Guidelines

• The European Society of Cardiology recommends ticagrelor as a standard P2Y12 inhibitor for acute coronary syndrome management, based on current guidelines from 2020 and other major societies 5, 6
• The FDA approved ticagrelor for use in acute coronary syndromes, with current guidelines recommending its use as a standard P2Y12 inhibitor 7, 9, 10